FAX Capital Corp. Sells 65,000 Shares of BioSyent Inc. (CVE:RX) Stock

BioSyent Inc. (CVE:RX) insider FAX Capital Corp. sold 65,000 shares of the company’s stock in a transaction that occurred on Thursday, April 13th. The stock was sold at an average price of C$7.70, for a total transaction of C$500,500.00.

FAX Capital Corp. also recently made the following trade(s):

• On Friday, November 22nd, FAX Capital Corp. sold 230,800 shares of BioSyent stock. The stock was sold at an average price of C$11.12, for a total transaction of C$2,566,496.00.

BioSyent Trading Down 0.1 %

CVE RX opened at C$11.51 on Thursday. The company has a market cap of C$133.40 million, a price-to-earnings ratio of 19.20 and a beta of 0.93. BioSyent Inc. has a twelve month low of C$8.24 and a twelve month high of C$11.74. The company has a quick ratio of 6.91, a current ratio of 6.13 and a debt-to-equity ratio of 3.19. The business’s fifty day moving average is C$11.08 and its 200 day moving average is C$10.32.

BioSyent (CVE:RX) last announced its quarterly earnings results on Monday, August 26th. The company reported C$0.13 EPS for the quarter, meeting analysts’ consensus estimates of C$0.13. The firm had revenue of C$8.95 million for the quarter, compared to analyst estimates of C$8.80 million. BioSyent had a return on equity of 20.88% and a net margin of 21.14%. As a group, sell-side analysts expect that BioSyent Inc. will post 0.6944444 EPS for the current fiscal year.

About BioSyent

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.